Argenx Nears Phase III In Myasthenia Gravis

 
• By John Davis

The reporting of positive topline Phase II results for a modified antibody fragment, efgartigimod, in myasthenia gravis by the Netherlands-based antibody-engineering biotech, argenx, has added to a growing list of new therapeutic approaches for the disorder.

Acetylcholine
Antibodies against acetylcholine receptors in neuromuscular junctions are a cause of myasthenia gravis • Source: Shutterstock

More from Clinical Trials

More from R&D